An immune attack can induce its own restraint: signals from responding T cells raise inhibitory proteins on nearby cells. This induced defence differs from resistance acquired after a treatment response.
The sequence proposed by Taube and colleagues and mapped in more detail since is a loop. A T cell recognises a tumour peptide on HLA and releases interferon gamma; the interferon acts through the Janus kinases JAK1 and JAK2 in nearby tumour and immune cells; PD-L1 rises; PD-L1 binds PD-1 on the T cell and damps it. In melanoma cell lines, Garcia-Diaz and colleagues found that the interferon gamma, JAK1 and JAK2, STAT1, STAT2 and STAT3, IRF1 axis primarily regulates PD-L1, with IRF1 binding the PD-L1 promoter, and biopsies from patients with melanoma showed enrichment of that interferon signature and of STAT and IRF1 target genes in tumours that responded to anti-PD-1 treatment.
PD-L1 is not the only brake that follows the attack. Spranger and colleagues found in human melanoma that the T-cell-inflamed tumours were the ones with high indoleamine 2,3-dioxygenase (IDO), PD-L1 and regulatory T cells, and in mice that all three depended on CD8 T cells being present: IDO and PD-L1 through interferon gamma, and regulatory T cells through CCR4-binding chemokines with some induced proliferation. Their reading was that these pathways are driven by the immune response rather than orchestrated by the cancer cells.
Evidence from tissue. In human melanocytic lesions, 98% of PD-L1-positive (B7-H1-positive) tumours had tumour-infiltrating lymphocytes compared with 28% of PD-L1-negative tumours; positive melanocytes sat almost always immediately next to lymphocytes, and interferon gamma was detected at the interface but not in PD-L1-negative tumours (Taube and colleagues). The same colocalisation appeared in inflamed benign naevi, which fits PD-L1 as a response to tissue inflammation. In triple-negative breast cancer, Gruosso and colleagues described an immunoreactive group whose tumours had granzyme B-positive CD8 T cells inside cancer-cell regions, a type 1 interferon signature and elevated IDO and PD-L1, the pattern adaptive resistance predicts; that is an association in tissue and not a direct test of the loop. The alternative, called innate or constitutive resistance, is PD-L1 driven by the cancer cell's own signalling regardless of T cells.
A functionally important loss of JAK1 or JAK2 can impair the tumour cell response to interferon gamma. In four people with metastatic melanoma that relapsed on anti-PD-1 treatment, two relapse samples carried loss-of-function JAK1 or JAK2 mutations with deletion of the remaining normal allele, and truncating JAK1 or JAK2 mutations left the cells unresponsive to interferon gamma (Zaretsky and colleagues). The JAK2-deficient relapse cells lost interferon-gamma-induced PD-L1 and class-I increases but retained responses to interferon alfa and beta. In engineered melanoma cells, JAK1 or JAK2 loss did not abolish recognition by the tested NY-ESO-1-specific T cells. Loss of inducibility is therefore different from absence of all baseline recognition. This selected series does not estimate a frequency for all cancers.
In plain words · PD-L1 can bind PD-1 and limit T-cell responses. It occurs on cancer and non-cancer cells; its use as a treatment-selection biomarker depends on the drug and setting.
Showing the target this term concerns: PD-L1.
Shares Immune exclusion, Cold tumours: immune deserts and exclusion, The cancer-immunity cycle, Hot vs cold tumours.
Shares CD4 T-cell subsets, Interferon-gamma gene signature (T-cell-inflamed signature), The cancer-immunity cycle.
Shares Immune exclusion, Cold tumours: immune deserts and exclusion, Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation.
Shares Interferon-gamma gene signature (T-cell-inflamed signature), Immune exclusion, Hot vs cold tumours.
Shares Immune surveillance and cancer immunoediting, Immune exclusion, Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation.
Shares Tumeh 2014: PD-1 blockade works by releasing T cells already present at the tumour edge, The cancer-immunity cycle, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1.
Shares Immune exclusion, Cold tumours: immune deserts and exclusion, Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation.
Shares Cold tumours: immune deserts and exclusion, Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/